title: Less mammographic density after nasal versus oral administration of postmenopausal hormone therapy.
abstract: OBJECTIVE
  Nasal administration gives a more acute but shorter rise in serum hormone levels than oral administration and may therefore have less effect on the fibroglandular tissue in the breasts. We studied the change in mammographic breast density after nasal vs. oral administration of postmenopausal hormone therapy (PHT).
  
  
  METHODS
  We studied participants in a randomized, controlled trial on the impact of nasal vs. oral administration of PHT (combined 17β-estradiol plus norethisterone) for 1 year. Two radiologists classified mammographic density at baseline and after 1 year into four categories. Also, the percentage density was calculated by a computer-based method. The main outcome measure was the difference in the proportion of women with an increase in mammographic density category after 1 year between the nasal and oral groups. Also, the change in the percentage density was calculated.
  
  
  RESULTS
  The study group comprised 112 healthy postmenopausal women (mean age 56 years), of whom 53 received oral and 59 intranasal PHT. An increase in mammographic density category after 1 year was seen in 20% of the women in the nasal group and in 34% of the oral group. This resulted in a non-significant difference in the proportion of women in whom mammographic breast density had increased by 214% (95% confidence interval (CI) 230% to 2.7%). The mean change in percentage density was 21.2% in the nasal group and + 1.2% in the oral group, yielding a 22.4% differential effect (95% CI 27.3% to 2.5%).
  
  
  CONCLUSIONS
  One year of nasal PHT gave a smaller, although not statistically significant, increase in mammographic density than oral PHT. Remaining issues are the relation between the route of administration of PHT and breast complaints and breast cancer risk.
authors.affiliation: Department of Epidemiology, Biostatistics and HTA, Radboud University Nijmegen Medical Centre, Nijmegen.
authors.forename: J A A M
authors.initials: JA
authors.lastname: van Dijck
authors.forename: J D M
authors.initials: JD
authors.lastname: Otten
authors.forename: N
authors.initials: N
authors.lastname: Karssemeijer
authors.forename: P
authors.initials: P
authors.lastname: Kenemans
authors.forename: A L M
authors.initials: AL
authors.lastname: Verbeek
authors.forename: M J
authors.initials: MJ
authors.lastname: van der Mooren
mesh_terms: D000281:Administration, Intranasal; D000284:Administration, Oral; D001943:Breast Neoplasms / Q000517:prevention & control; D003280:Contraceptives, Oral, Synthetic / Q000008:administration & dosage; D004311:Double-Blind Method; D004338:Drug Combinations; D004958:Estradiol / Q000008:administration & dosage*; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D008327:Mammography; D008875:Middle Aged; D009640:Norethindrone / Q000008:administration & dosage*; D017698:Postmenopause
chemical_list: D003280:Contraceptives, Oral, Synthetic; D004338:Drug Combinations; D004958:Estradiol; D009640:Norethindrone